Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer.
about
Novel radiotherapy approaches for lung cancer: combining radiation therapy with targeted and immunotherapiesMolecularly targeted drugs for metastatic colorectal cancerThe role of surgical intervention in lung cancer with carcinomatous pleuritisTumor Volume Estimation and Quasi-Continuous Administration for Most Effective Bevacizumab TherapyGemcitabine mono-therapy versus gemcitabine plus targeted therapy in advanced pancreatic cancer: a meta-analysis of randomized phase III trials.A consensus statement on the gender perspective in lung cancer.Results of a Phase II Trial of Carboplatin, Pemetrexed, and Bevacizumab for the Treatment of Never or Former/Light Smoking Patients With Stage IV Non-Small Cell Lung CancerEfficacy and tolerance of frontline bevacizumab-based chemotherapy for advanced non-small cell lung cancer patients: a multicenter, phase IV study of the Hellenic Oncology Research Group (HORG).Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions.Potential novel role of bevacizumab in glioblastoma and cervical cancer.Axitinib Improves Radiotherapy in Murine Xenograft Lung Tumors.Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Quantification of cell-free mSHOX2 Plasma DNA for therapy monitoring in advanced stage non-small cell (NSCLC) and small-cell lung cancer (SCLC) patients.Vascular endothelial growth factor is an autocrine growth factor, signaling through neuropilin-1 in non-small cell lung cancer.Efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment of non-small cell lung cancer: a systematic review and meta-analysis.A novel engineered VEGF blocker with an excellent pharmacokinetic profile and robust anti-tumor activityThe efficacy of combining antiangiogenic agents with chemotherapy for patients with advanced non-small cell lung cancer who failed first-line chemotherapy: a systematic review and meta-analysisPrediction of Clinical Outcome for All Stages and Multiple Cell Types of Non-small Cell Lung Cancer in Five Countries Using Lung Cancer Prognostic Index.Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of expertsMutational status of synchronous and metachronous tumor samples in patients with metastatic non-small-cell lung cancer.The impact of histological types on the efficacy of angiogenesis inhibitors in the treatment of advanced NSCLC: a meta-analysis of randomized controlled trialsPercutaneous CT-guided microwave ablation as maintenance after first-line treatment for patients with advanced NSCLCOverall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung CancerSEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015.Minimal change disease onset observed after bevacizumab administration.Real-world effectiveness of systemic agents approved for advanced non-small cell lung cancer: a SEER-Medicare analysis.Targeted therapies in non-small cell lung carcinoma: what have we achieved so far?Comparison of bevacizumab plus chemotherapy with chemotherapy alone in advanced non-small-lung cancer patientsA negative regulation loop of long noncoding RNA HOTAIR and p53 in non-small-cell lung cancer.Practical management of NSCLC patients with long-term bevacizumab treatment: a report of four cases.Second-Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological, and Molecular Aspects of Nintedanib.A Neuro-oncologist's Perspective on Management of Brain Metastases in Patients with EGFR Mutant Non-small Cell Lung Cancer.Bevacizumab in advanced NSCLC: chemotherapy partners and duration of use.Antiangiogenic agents and chemotherapy in advanced non-small cell lung cancer: a clinical perspective.Maintenance strategies in stage IV non-small-cell lung cancer (NSCLC): in which patients, with which drugs?Prognostic and predictive biomarkers in lung cancer. A review.Therapeutic strategy for non-small-cell lung cancer patients with brain metastases (Review).2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease.Mechanisms that influence tumour response to VEGF-pathway inhibitors.Cardiovascular Adverse Events in Patients With Cancer Treated With Bevacizumab: A Meta-Analysis of More Than 20 000 Patients.
P2860
Q26775388-D4A06C48-233E-4E02-8AF5-20B81C80EBA9Q26828735-D4F73E27-D7E4-487D-AD56-2AC1C730A299Q28068169-2758F856-043D-4A66-A776-84EEB84E410BQ28550733-47DDC13A-290C-4001-8785-19D2EA2D81C8Q30235450-6B4B09FE-A007-42F6-B530-3585BFA648F7Q30240700-3D6D541E-44B2-4B37-ACC3-A51BF26621C0Q33429242-E654EF0B-F914-4D27-AFE7-CCB0573D918BQ33433360-8C3D7C90-36B8-4608-9FD2-2E0803055479Q33770680-730E0980-EF53-469D-91EF-47F075F0CE8BQ34036070-45F0BD8F-64AE-4EBF-AB23-2E89CFCABBC4Q34092023-03A49BDC-224E-40D7-809B-02E2E3BDE24EQ34663877-F1EDEF65-4FB7-421D-810F-8C99C6BEB02FQ35078470-81DC0F39-CC71-4AE1-AC7B-B742A790A57DQ35358840-41A65AF7-4C31-4C4A-AFB3-DE807661535BQ35545472-23A06D17-1A14-41B3-9B39-D3FC09DCF8B5Q35604265-7F8B6204-0A81-4EAD-9B0B-BC64629D27F0Q35649624-B9C1BE04-E4A4-491E-9B40-FDC35B59671EQ35687989-4A87EFBE-2200-43B7-A5D9-A5A512A97E2BQ35909225-624F9D62-781D-490C-9BC3-B63345E8A6B4Q35954518-0A534ACC-9757-4E23-95DF-73ADE4D450A8Q36037036-EFE21146-7C40-40BB-B809-026C68108CC1Q36267763-0A492AA4-E4CA-4764-94E2-698B0B6FDA27Q36352827-D1E10A68-4915-4606-86C6-A19F8285484EQ36400216-CB419517-8329-4771-AC39-ACAC5EFDC798Q36689167-C777166E-31A8-49B0-8239-C4335E10C404Q36871717-267D74EA-3DE6-4553-BD9D-DD1426E5D1B4Q36999705-8B80530D-B2CC-4ACD-8FFB-B5183F20CC30Q37152528-BCDED16F-A9B6-4F01-AEA2-99BFF3109D7DQ37276552-68CB26A0-4D02-4A13-9E8B-33A4C3828303Q37566624-9CDE0E91-00E4-42B9-8894-1C9320673190Q37670497-1483008F-F07B-4156-820F-881F58666CE3Q37742623-83E05BE4-3A16-4E52-8FEA-75C9B1475764Q38132693-CD7E858D-3F8C-4057-8910-61FC62592873Q38153445-DB621D1F-38B7-4AEC-A30A-76910353C4A1Q38172326-9647E82C-3C67-44CF-98E8-41C1AB7E99CEQ38178187-48AD0044-01AA-48FF-8507-47A41A99E95CQ38197618-F5DEC72B-166A-468C-9493-8F37B4FDCE44Q38199478-4580A535-813D-4B13-915D-09E485A19A1DQ38268452-C2FDBBA2-B243-4A85-8E60-D44DDFA2A9EBQ38371293-EBCEFA4E-1FE3-49EE-9993-D75B1CB2A658
P2860
Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Systematic review and meta-ana ...... ed non-small-cell lung cancer.
@en
type
label
Systematic review and meta-ana ...... ed non-small-cell lung cancer.
@en
prefLabel
Systematic review and meta-ana ...... ed non-small-cell lung cancer.
@en
P2093
P2860
P31
P921
P356
P1433
P1476
Systematic review and meta-ana ...... ed non-small-cell lung cancer.
@en
P2093
A B Sandler
D Burcoveanu
D H Johnson
J-P Pignon
meta-analysis of bevacizumab in advanced NSCLC collaborative group
P2860
P356
10.1093/ANNONC/MDS590
P577
2012-11-23T00:00:00Z